<DOC>
	<DOCNO>NCT02529436</DOCNO>
	<brief_summary>Near 40 % French people age 65 year suffer Alzheimer disease associate disorder ( ADAD ) expose antidepressant ( AD ) versus 13 % without ADAD . If depression anxiety disorder comorbidities frequently associate dementia , level AD exposure suggest overuse AD population . Hypothesis : Overuse AD frequent patient ADAD . It possible assess overuse associate label prescription ( validated indication excess prescription duration ) Main objective : assess prevalence AD overuse associate label prescription ( validated indication excess prescription duration ) patient age 70 year ADAD . Secondary objective : 1 . To assess prevalence AD prescribe non validate indication 2 . To assess prevalence AD prescribe excess prescription duration 3 . To assess prevalence psychotropic coprescription notably prevalence neurologic iatrogenic alert define French National Authority Health 4 . To assess factor associate AD overuse Method : A transversal monocentric study geriatric day Bretonneau unit perform . Study propose eligible patient ( non-opposition patient legal representative collection personal data ) . Included people supplementary clinical complementary investigation . The geriatrician charge systematically collect indication history AD treatment . At end evaluation perform geriatric day unit , geriatrician conclude AD overuse associate label prescription . Doubtful case examine validation committee . Eligibility criterion : Patient consult geriatric day hospital age ≥70 year dementia accord DSMIV criterion , whatever level antidepressant prescription . Sample size Considering 40 % people suffer ADAD prescribe antidepressant ( data French Health Insurance ) , number eligible patient consult geriatric day swill 65 6 month . If 10 % oppose collection personal data overuse AD near 50 % , precision result 12.8 % ( 95 % CI bilateral ) . Duration inclusion : 6 month Duration patient 's participation : one day</brief_summary>
	<brief_title>Overuse Antidepressant Patients With Alzheimer Disease</brief_title>
	<detailed_description>According data French Health Insurance , near 40 % French people age 65 year suffer Alzheimer disease associate disorder ( ADAD ) expose antidepressant ( AD ) versus 13 % without ADAD . This confirm international data prevalence antidepressant prescription people ADAD range 26 % 56.4 % always superior population age . If depression anxiety disorder comorbidities frequently associate dementia , level AD exposure suggest overuse AD population . This overuse describe people live nursing home ( among , majority suffers ADAD ) would reach 62 % . To assess overuse demented people whatever place live necessary implement risk minimization action . Hypothesis : Overuse AD frequent patient ADAD . It possible assess overuse associate label prescription ( validated indication excess prescription duration ) transversal study . Main objective : To assess prevalence AD overuse associate label prescription ( validated indication excess prescription duration ) patient age 70 year ADAD . Secondary objective : 1 . To assess prevalence AD prescribe non validate indication 2 . To assess prevalence AD prescribe excess prescription duration 3 . To assess prevalence psychotropic coprescription notably prevalence neurologic iatrogenic alert define French National Authority Health : - Any prescription long half-life benzodiazepine ; - Of neuroleptic Alzheimer patient ; - Of 3 psychotropic drug ) 4 . To assess factor associate AD overuse Measurements : AD overuse label prescription , ie validate indication excess prescription duration : - Drug define AD include list AD design national French Task Force include expert 30 association scientific society ( N06AA02 Imipramine , N06AA04 Clomipramine , N06AA06 Trimipramine , N06AA09 Amitriptyline , N06AA10 Nortriptyline , N06AA17 Amoxapine , N06AA21 Maprotiline , N06AB03 Fluoxetine , N06AB04 Citalopram , N06AB05 Paroxetine , N06AB06 Sertraline , N06AB08 Fluvoxamine , N06AB10 Escitalopram , N06AF03 Phenelzine , N06AF04 Tranylcypromine , N06AF05 Iproniazide , N06AG02 Moclobemide , N06AX03 Mianserine , N06AX11 Mirtazapine , N06AX14 Tianeptine , N06AX16 Venlafaxine , N06AX17 Milnacipran , N06AX21 Duloxetine , N06AX22 Agomelatine ) - Indication AD one declare prescriber AD . This data collect direct contact prescriber medical report record interview patient 's caregiver . - Off label prescription define prescription indication list Summary Product Characteristics ( SPC ) . - Prescription duration consider exceed superior recommended market authorization : - Duration &gt; 14 month major depressive disorder patient remission - Exceeded duration accord geriatrician charge accord multidisciplinary evaluation perform geriatric day hospital . If geriatrician could conclude , expert committee ( include psycho-geriatrician geriatrician expert drug ) adjudicate overuse AD . Method : A transversal monocentric study geriatric day Bretonneau unit perform . Study propose eligible patient ( non-opposition patient legal representative collection personal data ) . Included people supplementary clinical complementary investigation . Data collect routinely geriatric day hospital include : Data collect nurse : socio-demographic data/ functional ability ( ADL IADL ) / professional caregiver home/ weight , pulse , blood pressure , orthostatic hypotension/ Zarit scale/ NeuroPsychiatric Inventory Data collect geriatrician : medical history , medication conciliation , clinical exam , screen depression ( miniGDS Cornell scale accord theMiniMental Status MMS score &gt; &lt; 18 ) , MMSif late score &gt; one year , Frontal assessment battery bedside ( FAB ) Psychologic psychiatric assessment neuropsychometric assessment perform accord indication cause assessment geriatric day hospital . The geriatrician charge systematically collect indication history AD treatment . At end evaluation perform geriatric day unit , geriatrician conclude AD overuse associate label prescription . Doubtful case examine validation committee ( psychogeriatrician geriatrician expert drug ) . Inclusion criterion : age ≥70 year / dementia accord DSMIV criterion , whatever level/ Antidepressant prescription Non inclusion criterion : opposition patient legal representative collection personal data/ Mild Cognitive Impairment Sample size Considering 40 % people suffer ADAD prescribe antidepressant ( data French Health Insurance ) , number eligible patient consult geriatric day swill 65 6 month . If 10 % oppose collection personal data overuse AD near 50 % , precision result 12.8 % ( 95 % CI bilateral ) . Duration inclusion : 6 month . Duration patient 's participation : one day .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Age ≥70 year , Dementia accord DSMIV criterion , whatever level , Antidepressant prescription . Refusal patient legal representative collection personal data , Mild Cognitive Impairment .</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>overuse antidepressant</keyword>
	<keyword>dementia</keyword>
</DOC>